Victory Capital Management Inc. Sells 576 Shares of Masimo Co. (NASDAQ:MASI)

Victory Capital Management Inc. trimmed its position in Masimo Co. (NASDAQ:MASI) by 5.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,240 shares of the medical equipment provider’s stock after selling 576 shares during the period. Victory Capital Management Inc.’s holdings in Masimo were worth $1,232,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in MASI. Farallon Capital Management LLC increased its stake in Masimo by 13.6% in the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after buying an additional 177,914 shares in the last quarter. Thrivent Financial for Lutherans grew its position in shares of Masimo by 42.1% during the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after purchasing an additional 360,497 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Masimo by 107.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock valued at $85,347,000 after purchasing an additional 351,523 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Masimo by 45.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock worth $66,201,000 after purchasing an additional 165,257 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in Masimo by 5.1% in the 2nd quarter. Marshall Wace LLP now owns 94,798 shares of the medical equipment provider’s stock worth $11,939,000 after purchasing an additional 4,591 shares during the period. 85.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Piper Sandler boosted their target price on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Wells Fargo & Company increased their price target on Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective on the stock in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $167.00.

Masimo Stock Down 3.1 %

Shares of MASI stock opened at $172.26 on Wednesday. Masimo Co. has a twelve month low of $91.60 and a twelve month high of $178.27. The stock has a market cap of $9.22 billion, a P/E ratio of 122.55 and a beta of 0.97. The stock has a 50 day moving average of $144.76 and a 200 day moving average of $128.38. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. As a group, sell-side analysts expect that Masimo Co. will post 4.04 EPS for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.